GLO1 and melanoma: If pharmacological target modulation phenocopies the changes caused by CRISPR/Cas9-based genetic target modulation, drug-like GLO1 inhibitors might emerge as a novel class of molecular therapeutics for the suppression of invasion and metastasis in malignant melanoma patients.